Companies / United Kingdom
GSK Buys Domantis
December 2006 | Company News AlertGSK intends to integrate Domantis into its Biopharmaceutical Centre of Excellence for Drug Discovery, which was established in 2003 to develop medicines in the booming biotech field. At inauguration, the centre's key programs were monoclonal antibodies for severe neurological disorders and therapeutic DNA vaccines for cancer and viral infections. However, in acknowledgement to Domantis' independent nature, the firm's activities will continue to take place at laboratories in Cambridge, the
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
